ArticleGynecologic oncology reports2025
Immune checkpoint Inhibitor-Induced Autoimmune hemolytic anemia in endometrial cancer.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Challenges in immunotherapy for the elderly: a case of refractory ICI-induced AIHA and thrombocytopenia in advanced gastric cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed management of advanced and recurrent endometrial carcinoma (EC). However, as their use increases, so too does the incidence of rare side effects related to their use. Here we describe a patient with stage IVB serous endometrial carcinoma who developed autoimmune hemolytic anemia (AIHA) following her second neoadjuvant cycle of carboplatin, paclitaxel, and dostarlimab. She was hospitalized, requiring multiple blood transfusions, a prolonged steroid course, and rituximab before stabilization of her anemia. Further cycles of chemotherapy without dostarlimab demonstrated good clinical response and did not reproduce AIHA. This case highlights the emerging multidisciplinary challenges that arise with the use of these novel targeted therapies. As the importance of these therapies increases in gynecologic oncologic management, it will be critical for providers to be able to diagnosis and manage their unique side effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.